Skip to content

Study · Animal study (in vivo) · mouse · 2020

10 results

Mitochondria targeted peptide SS-31 prevent on cisplatin-induced acute kidney injury via regulating mitochondrial ROS-NLRP3 pathway.

Yang SK, Han YC, He JR, Yang M, Zhang W, Zhan M, Li AM, Li L, Na-Song, Liu YT, Wu XQ, Zhang Q, Wang JW, Zhang H

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie24 Jul 2020Cited by 78 (Europe PMC)

PMID32717631 (opens in a new tab)DOI10.1016/j.biopha.2020.110521 (opens in a new tab)PepBankPUB-32717631
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-induced acute kidney injury, SS31 treatment suppressed mitochondrial reactive oxygen species.

    In plain wordsIn mice with cisplatin kidney injury, SS31 lowered mitochondrial reactive oxygen species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKidney mitochondrial ROS
    Study

    mousen: not reported in source

    Cisplatin-induced acute kidney injury (C57BL/6)
    Comparator
    CP + normal saline
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    10 mg/kg per day · 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS31 treatment could effectively suppress mitochondrial ROS, ameliorate these lesions and decrease the expression of NLRP3, IL-1β and Caspase1.
    1 context sentence
    Summary · context
    SS31 was administrated for 10 days at dosages of 10 mg/kg per day.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with cisplatin-induced acute kidney injury, SS31 treatment ameliorated the kidney lesions.

    In plain wordsIn mice with cisplatin kidney injury, SS31 reduced the kidney damage.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCisplatin-induced kidney lesions
    Study

    mousen: not reported in source

    Cisplatin-induced acute kidney injury (C57BL/6)
    Comparator
    CP + normal saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 mg/kg per day · 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS31 treatment could effectively suppress mitochondrial ROS, ameliorate these lesions and decrease the expression of NLRP3, IL-1β and Caspase1.
    1 context sentence
    Summary · context
    SS31 was administrated for 10 days at dosages of 10 mg/kg per day.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-induced acute kidney injury, SS31 treatment decreased NLRP3 expression.

    In plain wordsIn mice with cisplatin kidney injury, SS31 lowered NLRP3, an inflammation-related protein.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKidney NLRP3 expression
    Study

    mousen: not reported in source

    Cisplatin-induced acute kidney injury (C57BL/6)
    Comparator
    CP + normal saline
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 mg/kg per day · 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS31 treatment could effectively suppress mitochondrial ROS, ameliorate these lesions and decrease the expression of NLRP3, IL-1β and Caspase1.
    1 context sentence
    Summary · context
    SS31 was administrated for 10 days at dosages of 10 mg/kg per day.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-induced acute kidney injury, SS31 treatment decreased IL-1β expression.

    In plain wordsIn mice with cisplatin kidney injury, SS31 lowered IL-1β, an inflammation marker.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKidney IL-1β expression
    Study

    mousen: not reported in source

    Cisplatin-induced acute kidney injury (C57BL/6)
    Comparator
    CP + normal saline
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 mg/kg per day · 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS31 treatment could effectively suppress mitochondrial ROS, ameliorate these lesions and decrease the expression of NLRP3, IL-1β and Caspase1.
    1 context sentence
    Summary · context
    SS31 was administrated for 10 days at dosages of 10 mg/kg per day.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with cisplatin-induced acute kidney injury, SS31 treatment decreased caspase-1 expression.

    In plain wordsIn mice with cisplatin kidney injury, SS31 lowered caspase-1, an inflammation-related enzyme.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKidney caspase-1 expression
    Study

    mousen: not reported in source

    Cisplatin-induced acute kidney injury (C57BL/6)
    Comparator
    CP + normal saline
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 mg/kg per day · 10 daysAs given in this study (mouse).

    Source sentences

    Summary
    SS31 treatment could effectively suppress mitochondrial ROS, ameliorate these lesions and decrease the expression of NLRP3, IL-1β and Caspase1.
    1 context sentence
    Summary · context
    SS31 was administrated for 10 days at dosages of 10 mg/kg per day.
  6. 06LabIn vitro (cells)Mechanism

    In HK-2 cells exposed to cisplatin, SS31 restored the level of mitochondrial ROS.

    In plain wordsIn lab tests on kidney cells exposed to cisplatin, SS31 brought mitochondrial reactive oxygen species back down.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial ROS in HK-2 cells
    Study

    n: not reported in source

    HK-2 cells with cisplatin
    Comparator
    Cisplatin 50 µM
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    100 µMAs given in this study.

    Source sentences

    Summary
    In vitro studies, SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells, moreover, the elevated expression of NLRP3, IL-1β and Caspase-1were restored.
    1 context sentence
    Summary · context
    In vitro studies, HK-2 cells were incubated with cisplatin (50 u M) or combimed with SS-31(100 u M), the level of mitochondrial ROS, apoptosis rate and the the expression of NLRP3, Caspase-1 and IL-1β were tested.
  7. 07LabIn vitro (cells)Mechanism

    In HK-2 cells exposed to cisplatin, SS31 downregulated the apoptosis rate.

    In plain wordsIn lab tests on kidney cells exposed to cisplatin, SS31 lowered the rate of cell death by apoptosis.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseApoptosis rate in HK-2 cells
    Study

    n: not reported in source

    HK-2 cells with cisplatin
    Comparator
    Cisplatin 50 µM
    Outcome group
    Cell viability and death · Kidney and urinary
    Studied dose
    100 µMAs given in this study.

    Source sentences

    Summary
    In vitro studies, SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells, moreover, the elevated expression of NLRP3, IL-1β and Caspase-1were restored.
    1 context sentence
    Summary · context
    In vitro studies, HK-2 cells were incubated with cisplatin (50 u M) or combimed with SS-31(100 u M), the level of mitochondrial ROS, apoptosis rate and the the expression of NLRP3, Caspase-1 and IL-1β were tested.
  8. 08LabIn vitro (cells)Mechanism

    In HK-2 cells exposed to cisplatin, SS31 restored the elevated NLRP3 expression.

    In plain wordsIn lab tests on kidney cells exposed to cisplatin, SS31 brought raised NLRP3 back down.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNLRP3 expression in HK-2 cells
    Study

    n: not reported in source

    HK-2 cells with cisplatin
    Comparator
    Cisplatin 50 µM
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    100 µMAs given in this study.

    Source sentences

    Summary
    In vitro studies, SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells, moreover, the elevated expression of NLRP3, IL-1β and Caspase-1were restored.
    1 context sentence
    Summary · context
    In vitro studies, HK-2 cells were incubated with cisplatin (50 u M) or combimed with SS-31(100 u M), the level of mitochondrial ROS, apoptosis rate and the the expression of NLRP3, Caspase-1 and IL-1β were tested.
  9. 09LabIn vitro (cells)Mechanism

    In HK-2 cells exposed to cisplatin, SS31 restored the elevated IL-1β expression.

    In plain wordsIn lab tests on kidney cells exposed to cisplatin, SS31 brought raised IL-1β back down.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseIL-1β expression in HK-2 cells
    Study

    n: not reported in source

    HK-2 cells with cisplatin
    Comparator
    Cisplatin 50 µM
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    100 µMAs given in this study.

    Source sentences

    Summary
    In vitro studies, SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells, moreover, the elevated expression of NLRP3, IL-1β and Caspase-1were restored.
    1 context sentence
    Summary · context
    In vitro studies, HK-2 cells were incubated with cisplatin (50 u M) or combimed with SS-31(100 u M), the level of mitochondrial ROS, apoptosis rate and the the expression of NLRP3, Caspase-1 and IL-1β were tested.
  10. 10LabIn vitro (cells)Mechanism

    In HK-2 cells exposed to cisplatin, SS31 restored the elevated caspase-1 expression.

    In plain wordsIn lab tests on kidney cells exposed to cisplatin, SS31 brought raised caspase-1 back down.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCaspase-1 expression in HK-2 cells
    Study

    n: not reported in source

    HK-2 cells with cisplatin
    Comparator
    Cisplatin 50 µM
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    100 µMAs given in this study.

    Source sentences

    Summary
    In vitro studies, SS31 could restored the level of mitochondrial ROS and downregulate apoptosis rate in HK-2 cells, moreover, the elevated expression of NLRP3, IL-1β and Caspase-1were restored.
    1 context sentence
    Summary · context
    In vitro studies, HK-2 cells were incubated with cisplatin (50 u M) or combimed with SS-31(100 u M), the level of mitochondrial ROS, apoptosis rate and the the expression of NLRP3, Caspase-1 and IL-1β were tested.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.